País: Sudáfrica
Idioma: inglés
Fuente: South African Health Products Regulatory Authority (SAHPRA)
Lennon
INDICATIONS [/za_1307.html#1] [/za_1307.html#1] [/za_1307.html#1] CONTRA-INDICATIONS [/za_1307.html#1] [/za_1307.html#1] DOSAGE [/za_1307.html#1] [/za_1307.html#1] SIDE-EFFECTS [/za_1307.html#1] [/za_1307.html#1] [/za_1307.html#1] PREGNANCY [/za_1307.html#1] [/za_1307.html#1] OVERDOSE [/za_1307.html#1] IDENTIFICATION [/za_1307.html#1] [/za_1307.html#1] PATIENT INFORMATION INTRACEF 250 MG, 750 MG AND 1,5 G STERILE POWDER FOR INJECTION. SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): INTRACEF 250 MG, 750 MG AND 1,5 G STERILE POWDER FOR INJECTION. COMPOSITION: Vials containing 250 mg, 750 mg and 1,5 g CEFUROXIME as cefuroxime sodium. PHARMACOLOGICAL CLASSIFICATION: A 20.1.1 - Antimicrobial agents: Broad and medium spectrum antibiotics. PHARMACOLOGICAL ACTION: Cefuroxime is a bactericidal semi-synthetic cephalosporin antibiotic which is resistant to most ß-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms. Peak serum levels of cefuroxime are reached within 30 to 45 minutes after intramuscular administration. The serum half-life after either intramuscular or intravenous injection is approximately 70 minutes. Concurrent administration of probenecid produces an elevated peak serum level and restricts the excretion of the antibiotic. There is almost complete recovery of unchanged cefuroxime in the urine within 24 hours of administration the major part being eliminated within the first 6 hours. The tubular excretion component of renal clearance of cefuroxime is of the order of 50%. INDICATIONS: Cefuroxime is indicated for the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: Respiratory tract infections Ear, nose and throat infections Urinary tract infections Bone Leer el documento completo